Involvement of Environmental Mercury and Lead in the Etiology of Neurodegenerative Diseases

The incidence of neurodegenerative disease like Parkinson's disease and Alzheimer's disease (AD) increases dramatically with age; only a small percentage is directly related to familial forms. The etiology of the most abundant, sporadic forms is complex and multifactorial, involving both genetic and environmental factors. Several environmental pollutants have been associated with neurodegenerative disorders. The present article focuses on results obtained in experimental neurotoxicology studies that indicate a potential pathogenic role of lead and mercury in the development of neurodegenerative diseases. Both heavy metals have been shown to interfere with a multitude of intracellular targets, thereby contributing to several pathogenic processes typical of neurodegenerative disorders, including mitochondrial dysfunction, oxidative stress, deregulation of protein turnover, and brain inflammation. Exposure to heavy metals early in development can precondition the brain for developing a neurodegenerative disease later in life. Alternatively, heavy metals can exert their adverse effects through acute neurotoxicity or through slow accumulation during prolonged periods of life. The pro-oxidant effects of heavy metals can exacerbate the age-related increase in oxidative stress that is related to the decline of the antioxidant defense systems. Brain inflammatory reactions also generate oxidative stress. Chronic inflammation can contribute to the formation of the senile plaques that are typical for AD. In accord with this view, nonsteroidal anti-inflammatory drugs and antioxidants suppress early pathogenic processes leading to Alzheimer's disease, thus decreasing the risk of developing the disease. The effects of lead and mercury were also tested in aggregating brain-cell cultures of fetal rat telencephalon, a three-dimensional brain-cell culture system. The continuous application for 10 to 50 days of non-cytotoxic concentrations of heavy metals resulted in their accumulation in brain cells and the occurrence of delayed toxic effects. When applied at non-toxic concentrations, methylmercury, the most common environmental form of mercury, becomes neurotoxic under pro-oxidant conditions. Furthermore, lead and mercury induce glial cell reactivity, a hallmark of brain inflammation. Both mercury and lead increase the expression of the amyloid precursor protein; mercury also stimulates the formation of insoluble beta-amyloid, which plays a crucial role in the pathogenesis of AD and causes oxidative stress and neurotoxicity in vitro. Taken together, a considerable body of evidence suggests that the heavy metals lead and mercury contribute to the etiology of neurodegenerative diseases and emphasizes the importance of taking preventive measures in this regard.

[1]  J. Loike,et al.  Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils , 1996, Nature.

[2]  G. Bratton,et al.  Cellular targets of lead neurotoxicity: in vitro models. , 1986, Toxicology.

[3]  M. Zurich,et al.  Neurotoxicant-induced inflammatory response in three-dimensional brain cell cultures , 2007, Human & experimental toxicology.

[4]  Todd B. Sherer,et al.  Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.

[5]  Chantra Eskes,et al.  Maturation‐dependent neurotoxicity of lead acetate in vitro: Implication of glial reactions , 2002, Journal of neuroscience research.

[6]  M. Cini,et al.  Studies on lipid peroxidation and protein oxidation in the aging brain , 1995, Neurobiology of Aging.

[7]  T. Burbacher,et al.  Increases in the number of reactive glia in the visual cortex of Macaca fascicularis following subclinical long-term methyl mercury exposure. , 1994, Toxicology and applied pharmacology.

[8]  M. Navarro,et al.  Levels of selected metals in ambient air PM10 in an urban site of Zaragoza (Spain). , 2005, Environmental research.

[9]  M. Cameron Sullards,et al.  Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases* , 2006, Journal of Biological Chemistry.

[10]  R. Veerhuis,et al.  How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes , 2004, Aging cell.

[11]  M. Gilbert,et al.  Chronic developmental lead exposure reduces neurogenesis in adult rat hippocampus but does not impair spatial learning. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  G. Leuba,et al.  Involvement of microglia–neuron interactions in the tumor necrosis factor‐α release, microglial activation, and neurodegeneration induced by trimethyltin , 2003, Journal of neuroscience research.

[13]  D. Cory-Slechta Studying toxicants as single chemicals: does this strategy adequately identify neurotoxic risk? , 2005, Neurotoxicology.

[14]  K. Breen,et al.  The interaction between chronic low-level lead and the amyloid beta precursor protein. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[15]  D. Butterfield,et al.  In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42) , 1999, Neurobiology of aging.

[16]  David M. Umbach,et al.  Lead Exposure and Amyotrophic Lateral Sclerosis , 2002, Epidemiology.

[17]  C. Hock,et al.  Mercury Induces Cell Cytotoxicity and Oxidative Stress and Increases β‐Amyloid Secretion and Tau Phosphorylation in SHSY5Y Neuroblastoma Cells , 2000, Journal of neurochemistry.

[18]  D. Butterfield,et al.  Amyloid β-peptide inhibits Na+-dependent glutamate uptake , 1999 .

[19]  W. Streit Microglia and neuroprotection: implications for Alzheimer's disease , 2005, Brain Research Reviews.

[20]  M. Allam,et al.  Parkinson's disease risk factors: genetic, environmental, or both? , 2005, Neurological research.

[21]  J. Coyle,et al.  Oxidative stress in neurodegenerative diseases. , 1996, Annual review of pharmacology and toxicology.

[22]  G. Sandborgh-Englund,et al.  Mercury in saliva and feces after removal of amalgam fillings. , 1997, Toxicology and applied pharmacology.

[23]  Florianne Monnet-Tschudi,et al.  Microglial responsiveness as a sensitive marker for trimethyltin (TMT) neurotoxicity , 1995, Brain Research.

[24]  Hui Yang,et al.  Environmental toxins and α-synuclein in Parkinson’s disease , 2007, Molecular Neurobiology.

[25]  W. Streit,et al.  Microglia and Alzheimer's disease pathogenesis , 2004, Journal of neuroscience research.

[26]  T. Sherer,et al.  Environment, Mitochondria, and Parkinson's Disease , 2002, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[27]  John F Rosen,et al.  Low-level lead-induced neurotoxicity in children: an update on central nervous system effects , 1998, Brain Research Reviews.

[28]  F. Tsang,et al.  Interactions Between Environmental and Genetic Factors in the Pathophysiology of Parkinson's Disease , 2003, IUBMB life.

[29]  M. Zurich,et al.  Comparison of the developmental effects of two mercury compounds on glial cells and neurons in aggregate cultures of rat telencephalon , 1996, Brain Research.

[30]  T. Burbacher,et al.  Changes in the number of astrocytes and microglia in the thalamus of the monkey Macaca fascicularis following long-term subclinical methylmercury exposure. , 1996, Neurotoxicology.

[31]  J. O'Callaghan Neurotypic and gliotypic proteins as biochemical markers of neurotoxicity. , 1988, Neurotoxicology and teratology.

[32]  E. Nisbet,et al.  Can diamonds be dead bacteria? , 1994, Nature.

[33]  N. Fullwood,et al.  Protein aggregation, metals and oxidative stress in neurodegenerative diseases. , 2005, Biochemical Society transactions.

[34]  G. Bratton,et al.  Differential ability of astroglia and neuronal cells to accumulate lead: dependence on cell type and on degree of differentiation. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[35]  W. Tatton,et al.  Etiology and pathogenesis of Parkinson's disease. , 1999, Annual review of neuroscience.

[36]  G. Schettini,et al.  The amyloid precursor protein and its network of interacting proteins: physiological and pathological implications , 2005, Brain Research Reviews.

[37]  J. O'Callaghan,et al.  Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity , 2005, Expert opinion on drug safety.

[38]  B. Schilter,et al.  Increased vulnerability of neurones and glial cells to low concentrations of methylmercury in a prooxidant situation , 1998, Acta Neuropathologica.

[39]  J. O'Callaghan,et al.  Differential activation of microglia and astrocytes following trimethyl tin-induced neurodegeneration , 1996, Neuroscience.

[40]  B. Schilter,et al.  The Use of Serum-Free Aggregating Brain Cell Cultures in Neurotoxicology , 1995 .

[41]  F. Maxfield,et al.  Slow Degradation of Aggregates of the Alzheimer’s Disease Amyloid β-Protein by Microglial Cells* , 1997, The Journal of Biological Chemistry.

[42]  M. Zurich,et al.  Lead acetate toxicity in vitro: Dependence on the cell composition of the cultures. , 1998, Toxicology in vitro : an international journal published in association with BIBRA.

[43]  R. Mrak,et al.  Glial cytokines in Alzheimer's disease: review and pathogenic implications. , 1995, Human pathology.

[44]  S. Kohsaka,et al.  Microglia: neuroprotective and neurotrophic cells in the central nervous system. , 2004, Current drug targets. Cardiovascular & haematological disorders.

[45]  Ashima Bhan,et al.  Mercury in the Environment: Effect on Health and Reproduction , 2005, Reviews on environmental health.

[46]  D. Carpenter Effects of metals on the nervous system of humans and animals. , 2001, International journal of occupational medicine and environmental health.

[47]  D. Butterfield,et al.  Amyloid beta-peptide inhibits Na+-dependent glutamate uptake. , 1999, Life sciences.

[48]  D. Sparks,et al.  Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits , 1996, Journal of Molecular Medicine.

[49]  B. Bergamasco,et al.  Modifications of the iron–neuromelanin system in Parkinson's disease , 2006, Journal of neurochemistry.

[50]  C. Kaltschmidt,et al.  NF-kB: a crucial transcription factor for glial and neuronal cell function , 1997, Trends in Neurosciences.

[51]  C. Behl,et al.  Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application , 2005, International journal of experimental pathology.

[52]  Y. Dunant,et al.  Acetylcholine release and the cholinergic genomic locus , 1998, Molecular Neurobiology.

[53]  M. Mattson,et al.  Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. , 1994, Journal of neurochemistry.

[54]  F. Maxfield,et al.  Microglial Cells Internalize Aggregates of the Alzheimer's Disease Amyloid β-Protein Via a Scavenger Receptor , 1996, Neuron.

[55]  H. Walach,et al.  Alzheimer disease: mercury as pathogenetic factor and apolipoprotein E as a moderator. , 2004, Neuro endocrinology letters.

[56]  Cytotoxicity of microglia , 1993 .

[57]  M. Zurich,et al.  Evaluation of the toxicity of different metal compounds in the developing brain using aggregating cell cultures as a model. , 1993, Toxicology in vitro : an international journal published in association with BIBRA.

[58]  R. Mrak,et al.  Inflammatory Pathways: Implications in Alzheimer's Disease , 1996 .

[59]  L. Murri,et al.  Causative and susceptibility genes for Alzheimer’s disease: a review , 2003, Brain Research Bulletin.

[60]  S. Hirai,et al.  Expression of APP in the early stage of brain damage , 1991, Brain Research.

[61]  W. Streit,et al.  Reactive microgliosis , 1999, Progress in Neurobiology.

[62]  Y. Christen,et al.  Oxidative stress and Alzheimer disease. , 2000, The American journal of clinical nutrition.

[63]  M. Johnstone,et al.  A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced , 1999, Journal of Neuroimmunology.

[64]  J. Olson,et al.  Lead toxicity in primary cultured cerebral astrocytes and cerebellar granular neurons. , 1987, Toxicology and applied pharmacology.

[65]  T. Mandybur,et al.  Astrocytes and the plaques of Alzheimer's disease , 1990, Neurology.

[66]  J. Olson,et al.  Maturation of resistance to lead encephalopathy: cellular and subcellular mechanisms. , 1984, Neurotoxicology.

[67]  G. Benzi,et al.  Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. , 1995, Free radical biology & medicine.

[68]  S. Paul,et al.  The NF-κB/Rel family of proteins mediates Aβ-induced neurotoxicity and glial activation , 1998 .

[69]  J. Garrido,et al.  Amyloid precursor protein proteoglycan is increased after brain damage. , 1998, Biochimica et biophysica acta.

[70]  G. Kreutzberg Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[71]  Chantra Eskes,et al.  Microglial reaction induced by noncytotoxic methylmercury treatment leads to neuroprotection via interactions with astrocytes and IL‐6 release , 2002, Glia.

[72]  Philip J. Landrigan,et al.  Early Environmental Origins of Neurodegenerative Disease in Later Life , 2005, Environmental health perspectives.

[73]  R Brookmeyer,et al.  Age-specific incidence rates of Alzheimer’s disease , 2000, Neurology.

[74]  M. Mattson Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. , 1994, Journal of neurobiology.

[75]  L. Costa,et al.  Aggregating Brain Cell Cultures for Neurotoxicological Studies , 2004 .

[76]  W. Griffin,et al.  Glial‐Neuronal Interactions in Alzheimer's Disease: The Potential Role of a ‘Cytokine Cycle’ in Disease Progression , 1998, Brain pathology.

[77]  M. Aschner,et al.  Astrocytes as mediators of immune and inflammatory responses in the CNS. , 1998, Neurotoxicology.

[78]  M. Verity,et al.  Oxidative mechanisms underlying methyl mercury neurotoxicity , 1991, International Journal of Developmental Neuroscience.

[79]  G. Borsani,et al.  NF‐κB pathway: a target for preventing β‐amyloid (Aβ)‐induced neuronal damage and Aβ42 production , 2006, The European journal of neuroscience.

[80]  A. Harvey,et al.  Chronic gliosis triggers Alzheimer’s disease-like processing of amyloid precursor protein , 2002, Neuroscience.

[81]  M. Smith,et al.  Oxidative stress mechanisms and potential therapeutics in Alzheimer disease , 2005, Journal of Neural Transmission.

[82]  D. Butterfield,et al.  Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration , 2003, Journal of neurochemistry.

[83]  Louis W. Chang The Concept of Direct and Indirect Neurotoxicity and the Concept of Toxic Metal/Essential Element Interactions as a Common Biomechanism Underlying Metal Toxicity , 1992 .

[84]  G. Benzi,et al.  Are reactive oxygen species involved in Alzheimer's disease? , 1995, Neurobiology of Aging.

[85]  J. Growdon,et al.  Increased blood mercury levels in patients with Alzheimer's disease , 1998, Journal of Neural Transmission.

[86]  Ram Naresh,et al.  Blood lead levels in lactating cows reared around polluted localities; transfer of lead into milk. , 2005, The Science of the total environment.

[87]  B. Riederer,et al.  Effects of trimethyltin (TMT) on glial and neuronal cells in aggregate cultures: dependence on the developmental stage. , 1995, Neurotoxicology.

[88]  E. Tiffany-Castiglioni,et al.  Cell culture models for lead toxicity in neuronal and glial cells. , 1993, Neurotoxicology.

[89]  D. Borchelt,et al.  Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid β peptide in APPswe transgenic mice , 2003, Neurobiology of Disease.

[90]  V. Bolivar,et al.  Young brains on lead: adult neurological consequences? , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[91]  B. Giasson Mitochondrial injury: a hot spot for parkinsonism and Parkinson's disease? , 2004, Science of aging knowledge environment : SAGE KE.

[92]  A. Planas,et al.  MPP+ Injection into Rat Substantia Nigra Causes Secondary Glial Activation but Not Cell Death in the Ipsilateral Striatum , 2000, Neurobiology of Disease.

[93]  V. Yong,et al.  Astrocyte reactivity in neonatal mice: apparent dependence on the presence of reactive microglia/macrophages , 1996, Glia.

[94]  M. Smith,et al.  Genetic evidence for oxidative stress in Alzheimer's disease. , 1999, Neuroreport.

[95]  M. Sawada,et al.  Inflammatory process in Parkinson's disease: role for cytokines. , 2005, Current pharmaceutical design.

[96]  J. Gorell,et al.  Occupational Metal Exposures and the Risk of Parkinson’s Disease , 1999, Neuroepidemiology.

[97]  L. Costa,et al.  Involvement of glial cells in the neurotoxicity of parathion and chlorpyrifos. , 2004, Toxicology and applied pharmacology.

[98]  C. Levenson Iron and Parkinson's disease: chelators to the rescue? , 2003, Nutrition reviews.

[99]  G. Kreutzberg,et al.  Microglia, the first line of defence in brain pathologies. , 1995, Arzneimittel-Forschung.

[100]  S. Shankar,et al.  Aluminium in Alzheimer’s disease: are we still at a crossroad? , 2004, Cellular and Molecular Life Sciences CMLS.

[101]  A. Fontana,et al.  Astrocytes and lymphocytes: Intercellular communication by growth factors , 1982, Journal of neuroscience research.

[102]  N. Holbrook,et al.  Oxidants, oxidative stress and the biology of ageing , 2000, Nature.

[103]  O'Callaghan Jp,et al.  Assessment of neurotoxicity: use of glial fibrillary acidic protein as a biomarker. , 1991, Biomedical and environmental sciences : BES.

[104]  M. Zurich,et al.  Long-term treatment of aggregating brain cell cultures with low concentrations of lead acetate. , 1994, Neurotoxicology.

[105]  J. Gutteridge Hydroxyl Radicals, Iron, Oxidative Stress, and Neurodegeneration a , 1994, Annals of the New York Academy of Sciences.

[106]  B. Hyman,et al.  Neuroanatomy of Alzheimer's disease: Hierarchical vulnerability and neural system compromise , 1995, Neurobiology of Aging.

[107]  K. Jellinger,et al.  A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome , 1996, Brain Research.

[108]  B. Wolozin,et al.  Pathological proteins in Parkinson’s disease , 2007, Journal of Molecular Neuroscience.

[109]  Vellareddy Anantharam,et al.  Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis. , 2005, Neurotoxicology.

[110]  R. Hickel,et al.  Systemic transfer of mercury from amalgam fillings before and after cessation of emission. , 1998, Environmental research.

[111]  S. Bondy,et al.  Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. , 1992, Neurotoxicology.

[112]  Roberto Cappai,et al.  Metals and amyloid‐β in Alzheimer's disease , 2005, International journal of experimental pathology.

[113]  K. Breen,et al.  The role of glycoproteins in neural development, function, and disease , 1998, Molecular Neurobiology.

[114]  Georg W. Kreutzberg,et al.  Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function , 1999, Brain Research Reviews.

[115]  M. Rathbone,et al.  Involvement of astrocytes in purine-mediated reparative processes in the brain , 2001, International Journal of Developmental Neuroscience.

[116]  Y. K. Fung,et al.  Brain mercury in neurodegenerative disorders. , 1997, Journal of toxicology. Clinical toxicology.

[117]  D. Selkoe,et al.  Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β‐Protein , 2000, Annals of the New York Academy of Sciences.

[118]  Hui Yang,et al.  Environmental toxins and alpha-synuclein in Parkinson's disease. , 2005, Molecular neurobiology.

[119]  M. Mattson,et al.  Secreted Forms of β‐Amyloid Precursor Protein Protect Against Ischemic Brain Injury , 1994 .

[120]  J. Kordower,et al.  Etiology of Parkinson's disease: Genetics and environment revisited , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[121]  S. Paul,et al.  The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. , 1998, Brain research. Molecular brain research.